Candesartan, Metoprolol and Rosuvastatin Associated to Lower 30-Days Mortality in Adult COVID-19 Patients – A Register Study in Finland before COVID-19 Vaccines

Anna Hyvärinen, Mika Helminen, Markku Broas, Hannu Syrjälä, Department of Surgery, Tampere University Hospital, Wellbeing Services County of Pirkanmaa, Faculty of Medicine and Health Technology, Tampere University, Department of Surgery, Länsi-Pohja Central Hospital, Wellbeing Services County of Lapland, Department of Pediatric Surgery, Oulu University Hospital, Wellbeing Services County of Northern Ostrobothnia, Faculty of Medicine, University of Oulu, Faculty of Social Sciences, Health Sciences, Tampere University, Tays Research Services, Tampere University Hospital, Wellbeing Services County of Pirkanmaa, Department of Internal Medicine, Länsi-Pohja Central Hospital, Wellbeing Services County of Lapland, Department of Internal Medicine, Infection Control Unit, Lapland Central Hospital, Wellbeing Services County of Lapland, Division of Intensive Care Medicine, Research Group of Surgery, Anesthesiology and Intensive Care Medicine, Oulu University Hospital, Wellbeing Services County of Northern Ostrobothnia

Journal of Primary Care & Community Health

Published online on May 22, 2026

Abstract

Journal of Primary Care & Community Health, Volume 17, January-December 2026.
Elderly people with chronic diseases are at risk for having severe COVID-19 disease. We were interested whether the drugs prescribed for the chronic diseases are associated with lower mortality in COVID-19 patients.We used Finnish national registry data ...